(PDF) The Management of Chronic Myeloid Leukemia in the Era

The Management of Chronic Myeloid Leukemia in the Era of Second Generation Tyrosine Kinase Inhibitors

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi - Turkey

doi 10.4999/uhod.11011

Full Text

Abstract

Available in full text

Categories

Date

December 30, 2016

Authors

IBRAHIM CELALETTIN HAZNEDAROGLU

Publisher

Akademi Doktorlar Yayinevi

Related search

Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors

Clinical Lymphoma, Myeloma and Leukemia

Cancer Research

English

Use of Second Generation Tyrosine Kinase Inhibitors for Second-Line Treatment of Chronic Myeloid Leukemia After Imatinib Failure

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi

English

Thyroid Dysfunction Caused by Second-Generation Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

English

Arterial Events in Patients With Chronic Myeloid Leukemia Receiving Treatment With Second Generation Tyrosine Kinase Inhibitors

Klinicheskaya Onkogematologiya/Clinical Oncohematology

English

Use of Second- And Third-Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: An Evolving Treatment Paradigm

Clinical Lymphoma, Myeloma and Leukemia

Cancer Research

English

Management of Adverse Events Associated With Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia

Cancer Research

English

Complications of Tyrosine Kinase Inhibitors Therapy in Chronic Myeloid Leukemia - Chronic Phase

Revista de Chimie

Materials Science

Materials Chemistry

English

Future Perspectives of Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia

Chemotherapy: Open Access

English

Comparative Pharmacology of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia

International Journal of Clinical Pharmacology & Pharmacotherapy

English